Pfizer Names Dan R. Littman to Board of Directors
7 March 2018 - - New York, New York-based biopharmaceutical and healthcare products specialist Pfizer Inc. (NYSE: PFE) has appointed Dr. Dan R. Littman to its board of directors, and to the corporate governance and science and technology committees of the board, the company said.
Littman is the Helen L. and Martin S. Kimmel professor of molecular immunology at the Skirball Institute of Biomolecular Medicine of NYU Langone Medical Center and an investigator of the Howard Hughes Medical Institute. Prior to joining NYU in 1995, he was a professor of microbiology and immunology at the University of California, San Francisco.
Littman is also a member of the National Academy of the Sciences and the Institute of Medicine, and is a Fellow of the American Academy of Arts and Sciences and the American Academy of Microbiology.
Littman received an A.B. in Biochemical Sciences from Princeton University and an M.D. and Ph.D. from Washington University School of Medicine.
Pfizer discovers, develops, manufactures, and sells healthcare products worldwide. Its global portfolio includes medicines and vaccines as well as consumer health care products.
The company collaborates with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world.